# 1 Inference of SARS-CoV-2 generation times using UK household data

- 2 W.S. Hart<sup>1,\*</sup>, S. Abbott<sup>2</sup>, A. Endo<sup>2</sup>, J. Hellewell<sup>2</sup>, E. Miller<sup>3</sup>, N. Andrews<sup>4</sup>, P.K. Maini<sup>1</sup>, S.
- 3 Funk<sup>2,†</sup>, R.N. Thompson<sup>5,6,†</sup>

# 4 Affiliations:

- <sup>1</sup>Mathematical Institute, University of Oxford, Oxford, OX2 6GG, UK.
- 6 <sup>2</sup>Centre for Mathematical Modelling of Infectious Diseases, London School of Hygiene and
- 7 Tropical Medicine, London, WC1E 7HT, UK.
- 8 <sup>3</sup>Department of Infectious Disease Epidemiology, Faculty of Epidemiology & Population
- 9 Health, London School of Hygiene and Tropical Medicine, London, WC1E 7HT, UK.
- <sup>4</sup>Data and Analytical Sciences, Public Health England, London, UK.
- <sup>5</sup>Mathematics Institute, University of Warwick, Coventry, CV4 7AL, UK.
- <sup>6</sup>Zeeman Institute for Systems Biology and Infectious Disease Epidemiology Research,
- 13 University of Warwick, Coventry, CV4 7AL, UK.
- 14 \*Correspondence to: <u>william.hart@keble.ox.ac.uk</u>.
- 15 <sup>†</sup>These authors contributed jointly to this research
- 16

### 17 Abstract:

- 18 The distribution of the generation time (the interval between individuals becoming infected
- 19 and passing on the virus) characterises changes in the transmission risk during SARS-CoV-2
- 20 infections. Inferring the generation time distribution is essential to plan and assess public
- 21 health measures. We previously developed a mechanistic approach for estimating the
- 22 generation time, which provided an improved fit to SARS-CoV-2 data from January-March
- NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
   2020 compared to existing models. However, few estimates of the generation time exist

based on data from later in the pandemic. Here, using data from a household study conducted 24 from March-November 2020 in the UK, we provide updated estimates of the generation time. 25 26 We consider both a commonly used approach in which the transmission risk is assumed to be 27 independent of when symptoms develop, and our mechanistic model in which transmission 28 and symptoms are linked explicitly. Assuming independent transmission and symptoms, we 29 estimated a mean generation time (4.2 days, 95% CrI 3.3-5.3 days) similar to previous 30 estimates from other countries, but with a higher standard deviation (4.9 days, 3.0-8.3 days). 31 Using our mechanistic approach, we estimated a longer mean generation time (6.0 days, 5.2-32 7.0 days) and a similar standard deviation (4.9 days, 4.0-6.3 days). Both models suggest a 33 shorter mean generation time in September-November 2020 compared to earlier months. 34 Since the SARS-CoV-2 generation time appears to be changing, continued data collection and analysis is necessary to inform future public health policy decisions. 35

| 2 | C |
|---|---|
| J | О |

# **INTRODUCTION**

| 37 | The generation time of a SARS-CoV-2 infector-infectee pair is defined as the period of time      |
|----|--|
| 38 | between the infector and infectee each becoming infected [1–5]. The distribution of the          |
| 39 | generation times of many infector-infectee pairs characterises the temporal profile of           |
| 40 | infectiousness of an infected host (averaged over all hosts and normalised so that it represents |
| 41 | a valid probability distribution) [6]. Inferring the generation time distribution of SARS-CoV-   |
| 42 | 2 is important in order to predict the effects of non-pharmaceutical interventions such as       |
| 43 | contact tracing and quarantine [7, 8]. In addition, the generation time distribution is widely   |
| 44 | used in epidemiological models for estimating the reproduction number from case                  |
| 45 | notification data [6, 9–11] and is crucial for understanding the relationship between the        |
| 46 | reproduction number and the epidemic growth rate [3, 6].   |
| 47 |  |
| 48 | The SARS-CoV-2 generation time distribution has previously been estimated using data from        |
| 49 | known infector-infectee transmission pairs [8, 12, 13] or entire clusters of cases [14-16].      |
| 50 | These studies involved data [8, 14, 17–20] collected between December 2019 and April 2020,       |
| 51 | almost all from countries in East and Southeast Asia (with the exception of four transmission    |
| 52 | pairs from Germany and four from Italy in [8]). Evidence from January and February 2020 in       |
| 53 | China suggested a temporal reduction in the mean generation time due to non-pharmaceutical       |
| 54 | interventions [15]. Specifically, effective isolation of infected individuals is likely to have  |
| 55 | reduced the proportion of transmissions occurring when potential infectors were in the later     |
| 56 | stages of infection, thereby shortening the generation time [15]. Similarly, two other studies   |
| 57 | found a decrease in the serial interval (the difference between symptom onset times of an        |
| 58 | infector and infectee) [21] and an increase in the proportion of presymptomatic transmissions    |
| 59 | [22] in China over the same time period, which can be attributed to symptomatic hosts being      |
| 60 | isolated increasingly quickly over time.   |

61

| 62 | Despite estimation of the SARS-CoV-2 generation time in Asia early in the pandemic,            |
|----|--|
| 63 | relatively little is known about the generation time distribution outside Asia, and whether or |
| 64 | not any changes have occurred in the generation time since the early months of the pandemic.   |
| 65 | In particular, we are aware of only one study in which the generation time was estimated       |
| 66 | using data from the UK [23]. In that study [23], data describing symptom onset dates for 50    |
| 67 | infector-infectee pairs, collected by Public Health England between January and March 2020     |
| 68 | as part of the "First Few Hundred" case protocol [24, 25], were used to infer the generation   |
| 69 | time distribution. However, since these transmission pairs mostly consisted of international   |
| 70 | travellers and their household contacts, the authors concluded that their estimates of the     |
| 71 | generation time may have been biased downwards due to enhanced surveillance and isolation      |
| 72 | of these cases [23].   |

73

74 Here, we use data from a household study, conducted between March and November 2020, to estimate the SARS-CoV-2 generation time distribution in the UK under two different 75 76 underlying transmission models. In the first model (the "independent transmission and 77 symptoms model"), a parsimonious assumption is made that the generation time and the 78 incubation period of the infector are independent (i.e., there is no link between the times at 79 which infectors transmit the virus and the times at which they develop symptoms), as has 80 often been employed in studies in which the SARS-CoV-2 generation time has been 81 estimated [8, 12–14, 23, 26] (Table 1). In the second model (the "mechanistic model"), we 82 use a mechanistic approach in which potential infectors progress through different stages of 83 infection, first becoming infectious before developing symptoms [12]. Infectiousness is therefore explicitly linked to symptoms in the mechanistic model. By fitting separately to 84 data from three different time intervals within the study period, we explore whether or not 85

- there was a detectable temporal change in the generation time distribution. Our study
- 87 represents the first analysis of the SARS-CoV-2 generation time outside Asia conducted
- using data from after the earliest stages of the pandemic.
- 89

| Study                   | Location  | Time period                           | Mean<br>generation<br>time (days) | Standard<br>deviation of<br>generation<br>times (days) |
|-------------------------|-----------|---------------------------------------|-----------------------------------|--|
| Ferretti et al.<br>[8]  | Various   | December<br>2019-<br>February<br>2020 | 5.0                               | 1.9  |
| Ganyani et<br>al. [14]  | Singapore | January-<br>February<br>2020          | 5.20 (3.78-<br>6.78)              | 1.72 (0.91-<br>3.93)                                   |
| Ganyani et<br>al. [14]  | China     | January-<br>February<br>2020          | 3.95 (3.01-<br>4.91)              | 1.51 (0.74-<br>2.97)                                   |
| Hart et al.<br>[12]     | Various   | December<br>2019-March<br>2020        | 5.57 (5.08-<br>6.09)              | 2.32 (1.83-<br>2.91)                                   |
| Ferretti et al.<br>[13] | Various   | December<br>2019-March<br>2020        | 5.5                               | 1.8  |
| Challen et al. [23]     | UK        | January-<br>March 2020                | 4.8 (4.3-<br>5.41)                | 1.7 (1.0-2.6)  |

- Table 1. Previous SARS-CoV-2 generation time estimates. Estimates of the mean and standard deviation of
   the generation time distribution, obtained under the assumption of independent transmission and symptoms.
   95% credible intervals are shown in brackets where available.
   94
   95
   RESULTS
   96 Inferring generation times from UK household data
   97 We used data augmentation MCMC to fit two models of infectiousness (the independent
   98 transmission and symptoms model and the mechanistic model) to data describing individuals'
- 99 infection status and symptom onset dates in 172 UK households (see Methods). For the two
- 100 fitted models, we calculated posterior estimates of the mean (Figure 1A) and standard

101 deviation of the generation time distribution (Figure 1B), in addition to the proportion of 102 transmissions occurring prior to symptom onset (among infectors who develop symptoms; 103 Figure 1C) and the overall infectiousness parameter,  $\beta_0$  (see Methods; Figure 1D). Under the 104 commonly used independent transmission and symptoms model, we obtained a point estimate 105 (posterior mean) of 4.2 days (95% CrI 3.3-5.3 days) for the mean generation time (Figure 1A, 106 blue violin). This value is similar to a previous estimate using data from China in [14], and is 107 slightly lower than estimates for Singapore in [14] and for several countries (predominantly 108 in Asia) in [8] (Table 1), although those estimates lie within our credible interval. On the 109 other hand, our estimated standard deviation of 4.9 days (95% CrI 3.0-8.3 days; Figure 1B, 110 blue violin) is substantially higher than previous estimates (Table 1). Using our mechanistic 111 model, we obtained a higher estimate for the mean generation time of 6.0 days (95% CrI 5.2-112 7.0 days; Figure 1A, red violin), and a similar estimate for the standard deviation (4.9 days, 95% CrI 4.0-6.3 days; Figure 1B, red violin), compared to those predicted by the independent 113 114 transmission and symptoms model. The two models gave similar posterior distributions for 115 the proportion of transmissions prior to symptom onset (Figure 1C), with point estimate 116 values of model parameters generating estimates of 0.72 (95% CrI 0.63-0.80) for the 117 independent transmission and symptoms model, and 0.73 (95% CrI 0.61-0.83) for the 118 mechanistic model.





130



128 Posterior distributions and point estimates (posterior means) for all fitted model parameters 129 are shown in the Supplementary Material (Figures S1-S2 and Tables S2-S3). Since only the likelihood with respect to augmented data was calculated in the MCMC procedure, explicit

comparisons of goodness of fit between the models were not readily available. However,
comparing model predictions of the difference between successive symptom onset dates with
the UK household data indicated that both models provided a similar fit to the data (Figure
S3).

135

136 As described in Methods, the generation time distribution that we considered in Figure 1 (and 137 elsewhere, unless otherwise stated) corresponds to the normalised expected infectiousness 138 profile of a host at each time since infection. However, realised generation times are expected 139 to be shorter for infected individuals in small households compared to those in large 140 households. This is due to depletion of susceptible household members in small households 141 before longer generation times can be attained [6, 27]. As a result, we also predicted the mean and standard deviation of realised generation times within the study households (Figure S4A-142 143 B), accounting for the precise distribution of household sizes in the study. For both the 144 independent transmission and symptoms model and the mechanistic model, point estimates 145 for the mean (3.6 days and 4.9 days for the two models, respectively) and standard deviation 146 (3.8 days and 4.1 days) of realised household generation times were lower than those shown 147 in Figure 1. Since transmission then typically occurred earlier in the infector's course of infection than shown in Figure 1, we predicted a higher proportion of presymptomatic 148 149 transmissions within the study households (Figure S4C) compared to the estimates in Figure 1C. 150

151

152 For both models, we then used point estimates of fitted model parameters to infer the

153 distributions of the generation time (Figure 2A), the time from onset of symptoms to

154 transmission (TOST; Figure 2B) and the serial interval (Figure 2C). The TOST distribution

155 (which characterises the relative expected infectiousness of a host at each time from symptom

onset, as opposed to from infection [13, 20, 26, 28, 29]) predicted using the mechanistic
model was more concentrated around the time of symptom onset compared to that obtained
using the independent transmission and symptoms model (Figure 2B), as was found in [12].
In contrast, the estimated serial interval distributions were similar for the two models (Figure 2C).





Figure 2. Generation time, TOST and serial interval distributions. Inferred generation time (A), TOST (B)
and serial interval (C) distributions for the two models, obtained using point estimate (posterior mean)
parameters. Note that the discontinuity in the red curve in Figure 2B occurs because two different transmission
rates were fitted for infectors in the presymptomatic and symptomatic periods. The reduction in transmission
following symptom onset can be attributed to changes in behaviour in response to symptoms [30].

167

### 168 <u>Temporal variation in the generation time distribution</u>

- 169 To explore whether or not the generation time distribution changed during the study period,
- 170 we separately fitted the independent transmission and symptoms model to the data from
- 171 households in which the index case was recruited in (i) March-April, (ii) May-August, or (iii)
- 172 September-November 2020 (Figure 3). We chose these time periods to ensure the numbers of
- 173 households recruited into the study during each interval were similar (Figure S5).

medRxiv preprint doi: https://doi.org/10.1101/2021.05.27.21257936; this version posted May 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.





Figure 3. Temporal changes in the generation time distribution. Violin plots indicating posterior
distributions of the mean generation time (A), standard deviation of generation times (B), and overall
infectiousness parameter, β<sub>0</sub> (C), for the independent transmission and symptoms model fitted to data from
March-April (blue), May-August (red) or September-November 2020 (orange).

179

180 The results shown in Figure 3A suggest a lower mean generation time in September-

181 November (2.9 days, 95% CrI 1.8-4.3 days) compared to earlier months (4.9 days, 95% CrI

182 3.6-6.3 days, for March-April and 5.2 days, 95% CrI 3.4-7.2 days, for May-August). A

183 similar temporal reduction in the mean generation time was found when we instead fitted the

184 mechanistic model to the data from the three time intervals (Figure S6A). To explore the

185 lower estimated generation time for September-November further, we also fitted the

186 independent transmission and symptoms model to the data from each of these months

187 individually (Figure S7). The shorter estimated generation time compared to earlier in the

188 pandemic was consistent in each of the three months (Figure S7A).

189

190 <u>Sensitivity analyses</u>

191 In the independent transmission and symptoms model, we assumed that both the generation

192 time and incubation period followed lognormal distributions. The mean and standard

- 193 deviation of the generation time distribution were estimated by fitting the model to the
- 194 household transmission data. In the fitting procedure, we assumed that the incubation period

195 followed a lognormal distribution that was obtained in a previous meta-analysis [31]. In 196 contrast, we assumed in our mechanistic approach that each infection could be decomposed 197 into three gamma distributed stages (latent, presymptomatic infectious and symptomatic 198 infectious), so that the incubation period was also gamma distributed (with the same mean 199 and standard deviation as the lognormal distribution obtained in [31]). An expression for the 200 generation time distribution in the mechanistic model, which did not take a simple parametric 201 form, is given in the Supplementary Text. However, we conducted supplementary analyses in 202 which we instead assumed that either the generation time (Figure S8A-C) or incubation 203 period (Figure S8D-F) in the independent transmission and symptoms model was gamma 204 distributed. In both cases, we obtained similar results to those shown for that model in Figure 205 1.

206

In Figure S9, we relaxed the assumption of a fixed incubation period distribution, using the
confidence intervals obtained in [31] to account for uncertainty in the incubation period
distribution (Figure S9A-B). For both the independent transmission and symptoms model and
the mechanistic model, accounting for this uncertainty did not substantially affect posterior
estimates of either the mean (Figure S9C) or the standard deviation (Figure S9D) of the
generation time distribution.

213

In our main analyses, we assumed that household transmission was frequency-dependent, so that the force of infection exerted by an infected household member on each susceptible household member scaled with 1/n, where *n* is the household size. In order to explore the robustness of our results to this assumption, we considered alternative possibilities where infectiousness scaled with  $n^{-\rho}$ , for  $\rho = 0$  (density-dependent transmission) and  $\rho = 0.5$ (Figure S10A-B). We also conducted an analysis in which the dependency,  $\rho$ , was estimated

alongside other model parameters (Figure S10C). We found that our estimates of the mean 220 221 and standard deviation of the generation time distribution were robust to the assumed value of 222  $\rho$  (Figure S10A-B). However, when the value  $\rho$  was fitted (Figure S10C), we estimated a value of 1.0 (95% CrI 0.6-1.5). This supported our assumption of frequency-dependent 223 224 transmission, although the credible interval was relatively wide. In addition, we considered 225 the possibility that infectiousness instead scales with 1/(n-1), so that the infectious individual is removed from the scaling in the force of infection  $\beta(\tau)$ , and again obtained 226 similar estimates of the mean and standard deviation of the generation time distribution 227 228 compared to those shown in Figure 1 (Figure S10D-E). 229

We also considered the sensitivity of our results to the assumed relative infectiousness of 230 231 asymptomatic infected hosts (Figure S11). In most of our analyses, we assumed that the 232 expected infectiousness of an infected host who remained asymptomatic throughout infection was a factor  $\alpha_A = 0.35$  times that of a host who develops symptoms, at each time since 233 234 infection [31]. However, similar estimates of the mean (Figure S11A) and standard deviation 235 (Figure S11B) of the generation time distribution were obtained when we instead assumed  $\alpha_A = 0.1$  or  $\alpha_A = 1.27$  (these values corresponded to the lower and upper confidence bounds 236 237 obtained in [32]).

238

Finally, we explored the robustness of our results to the exclusion of hosts with unknown infection status (see Methods), considering the extreme possibilities where these hosts were instead assumed to have either all remained uninfected, or all become infected (Figure S12). Although the estimates of  $\beta_0$  were affected by this assumption (Figure S12C), the estimated generation time distribution was robust to the assumed infection status of these hosts (Figure S12A-B).

245

#### 246

### DISCUSSION

247 In this study, we estimated the generation time distribution of SARS-CoV-2 in the UK by 248 fitting two different models to data describing the infection status and symptom onset dates of 249 individuals in 172 households. The first of these models was predicated on an assumption 250 that transmission and symptoms are independent. While this assumption has often been made 251 in previous studies in which the SARS-CoV-2 generation time has been estimated [8, 14, 23, 252 33, 34], it is not an accurate reflection of the underlying epidemiology [26, 35]. Therefore, we 253 also considered a mechanistic model based on compartmental modelling, which was shown 254 in [12] to provide an improved fit to data from 191 SARS-CoV-2 infector-infectee pairs 255 compared to previously used models that have been used to estimate the generation time. 256 Here, infection times and the order of transmissions within households were unknown, whereas in [12] the direction of transmission was assumed to be known for each infector-257 258 infectee pair. For that reason, we used data augmentation MCMC to fit the two models to the 259 household data, in a similar fashion to previous studies of household influenza virus 260 transmission [27, 36, 37].

261

Under the model assuming independent transmission and symptoms, we estimated a mean 262 generation time of 4.2 days (95% CrI 3.3-5.3 days) and a standard deviation of 4.9 days (95% 263 264 CrI 3.0-8.3 days). The estimate of the mean generation time was comparable to previous estimates obtained under this assumption using data from elsewhere [8, 13, 14] (Table 1). On 265 266 the other hand, while our credible interval for the standard deviation was wide, the estimates 267 obtained in those previous studies [8, 13, 14] all lay below our lower 95% credible limit of 3.0 days. One potential cause of this disparity is the difference in isolation policies for 268 269 symptomatic hosts between countries. In particular, the UK's policy of self-isolation may be

expected to lead to a longer-tailed generation time distribution compared to countries with a
policy of isolation outside the home, since under home isolation, some within-household
transmission is likely to occur even following isolation. Isolation outside the home was
commonplace in the East and Southeast Asian countries where the majority of the data
underlying the estimates in [8, 13, 14] were collected. Because we used only household
transmission data, this effect was likely to be particularly pronounced in our estimates.

276

277 Using the mechanistic model, we predicted a higher mean generation time of 6.0 days (95% 278 CrI 5.2-7.0 days) compared to the value estimated under the assumption of independent 279 transmission and symptoms. On the other hand, the inferred serial intervals for the 280 independent transmission and symptoms model and mechanistic model were similar (Figure 281 2C), with means of 4.2 days and 4.7 days, respectively. Temporal information in our household transmission data consisted mostly of symptom onset dates, with very few hosts 282 283 testing positive before developing symptoms. Therefore, the variation in estimates of the generation time between the models can be attributed to differences in the assumed 284 285 relationships between the generation time and serial interval under those models. For the 286 independent transmission and symptoms model, the generation time and serial interval distributions have the same mean, as is commonly assumed to be the case [26]. However, this 287 288 was not true for the mechanistic model, in which hosts with longer presymptomatic infectious 289 periods generate (on average) a higher number of transmissions. As a result, under the 290 mechanistic model, a randomly chosen infection is likely to arise from an infector with a 291 longer than expected incubation period, thereby leading to a longer generation time than 292 serial interval (an analytical expression for the exact difference between the mean generation 293 time and serial interval for that model is derived in the Supplementary Material).

294

Our results did not indicate any clear difference in goodness of fit between the two models 295 296 (Figure S3). A range of factors should therefore be considered when deciding which of our 297 estimates of epidemiological parameters to use in subsequent analyses. Although any model 298 requires simplifying assumptions to be made, our mechanistic approach allows the standard 299 assumption of independent transmission and symptoms to be relaxed by providing a 300 mechanistic underpinning to the relationship between the times at which individuals display 301 symptoms and become infectious. Furthermore, as described above, this model was shown in 302 [12] to provide a better fit to another SARS-CoV-2 dataset than a model assuming 303 independence between transmission and symptoms (in [12], the simpler setting of 304 transmission pairs rather than households facilitated direct model comparison). On the other 305 hand, the independent transmission and symptoms model has the advantage of producing an 306 estimated generation time distribution with a simple parametric form. The choice of estimates 307 to use may also depend on precisely what the estimates are being used for. For example, the 308 generation time distribution inferred under the assumption of independent transmission and 309 symptoms may be better suited for use in some models for estimating the time-dependent 310 reproduction number, since those models often also implicitly involve the assumption that 311 transmission and symptoms are independent [10]. In contrast, the parameter estimates from our mechanistic approach correspond naturally to parameters in compartmental epidemic 312 313 models.

314

By fitting separately to data from three different intervals within the study period (March-November 2020), we investigated whether or not the generation time distribution in the UK changed as the pandemic progressed. Our results indicate a lower mean generation time in September-November compared to earlier months (Figure 3A). One possible explanation for this is a higher proportion of time spent indoors in colder months leading to an increased

household transmission risk, particularly in the early stages of infection before symptoms
develop (since symptomatic infected hosts are still likely to self-isolate). While shorter
generation times may in general be over-represented in data collected from infector-infectee
pairs at times when case numbers are rising [8, 26, 38] (as was the case in September and
October [39, 40]), we estimated the mean generation time to be similar in November (when
national case numbers were mostly decreasing [39, 40]) compared to September and October
(Figure S7).

327

Our finding of a temporal decrease in the mean generation time during the study period highlights the importance of obtaining up-to-date generation time estimates specific to the location under study. Should variations in the generation time distribution occur and not be accounted for, estimates of the time-dependent reproduction number may be incorrect [3, 41]. Specifically, if the mean generation time is shorter than assumed, then the true value of the time-dependent reproduction number is closer to one than the inferred value [3] (and vice versa).

335

336 The B1.1.7 SARS-CoV-2 variant [42], which has since become the dominant lineage in the UK, was responsible for infections in only two households within our dataset. Therefore, 337 additional data are needed to quantify the impact of the emergence of this variant on the 338 339 generation time. A shorter mean generation time of the B1.1.7 variant has been hypothesised 340 as one possible contribution to the increased growth rate of cases in the UK in late 2020 and 341 early 2021, but a decrease in the generation time alone was not found to explain trends in UK case data [43, 44]. Conversely, viral load data suggest a longer duration of viral shedding due 342 343 to infection with B1.1.7 compared to the original variant of SARS-CoV-2 [45]. If higher viral

loads lead to increased infectiousness [46–50], this may suggest a longer-tailed generation
time distribution for the B1.1.7 variant.

346

347 One advantage of our approach is that we are able to include the contribution of 348 asymptomatic infected hosts to household transmission chains in our analyses. We showed 349 that our estimated generation time distribution was robust to the assumed relative 350 infectiousness of infected hosts who remained asymptomatic,  $\alpha_A$  (Figure S11). Similarly, while we assumed frequency-dependent household transmission in most of our analyses, we 351 352 found that the exact relationship between the household size and transmission rate had little 353 effect on our estimates of the mean and standard deviation of the generation time distribution 354 (Figure S10). We also considered estimating the exponent governing the dependency of 355 transmission on household size (Figure S10C). This supported our assumption of frequencydependent transmission. In previous studies of influenza transmission within households, 356 357 evidence has been found both in favour of [36] and against [51] frequency-dependent 358 transmission.

359

360 Our study has some limitations. Since we used household transmission data in our analyses, the generation time for transmission outside the household may differ from our estimates. 361 362 Future extensions to our approach may account for the possibility that more than one 363 household member was infected in the same primary infection event or the potential for 364 multiple sequential introductions of the virus into a household [37]. Allowing for multiple 365 introductions may shorten estimates of the generation time, although any effect will dependent significantly on the community prevalence and the number of contacts that 366 367 household members have with individuals in the community. In contrast, accounting for 368 potential co-primary infections is likely to lead to higher estimates of the generation time.

| 369 | Other further work may include exploring heterogeneity in the generation time distribution       |
|-----|--|
| 370 | between individuals and/or households with different characteristics. This could involve, but    |
| 371 | is not limited to, estimating the generation time distribution for individuals of different age, |
| 372 | sex and ethnicity.   |
| 373 |  |
| 374 | In summary, we have inferred the SARS-CoV-2 generation time distribution in the UK using         |
| 375 | household data and two different transmission models. A key output of this research is one of    |
| 376 | the only estimates of the SARS-CoV-2 generation time outside Asia. Another crucial feature       |
| 377 | of our analysis is that it was based on data from beyond the first few months of the pandemic.   |
| 378 | Since this research suggests that the generation time may be changing, continued data            |
| 379 | collection and analysis is of clear importance.  |
| 380 |  |
| 381 | METHODS  |
| 382 | Data   |
| 383 | Data were obtained from a household study conducted by Public Health England in 172              |
| 384 | households (with 603 household members in total) between March and November 2020. In             |
| 385 | each household, an index case was recruited following a positive PCR test. The following         |
| 386 | were then recorded for each household member:  |
| 387 | • The timing and outcome of (up to) two subsequent PCR tests.                                    |
| 388 | • The outcome of an antibody test (carried out for 90% of individuals).                          |
| 389 | • Whether or not the household member developed symptoms.  |
| 390 | • The date of symptom onset (only for symptomatic individuals with a positive PCR or             |
| 391 | antibody test).  |
| 392 |  |

393 In the study, all household members who tested positive in either a PCR or antibody test were 394 assumed to have been infected. Conversely, all individuals who tested negative for antibodies 395 (and where the two PCR tests were either negative or were not carried out) were assumed to 396 have remained uninfected, irrespective of symptom status. For 6% of the study cohort, no 397 antibody test was carried out and any PCR tests were negative. These hosts with unknown 398 infection status were excluded from our main analyses (but were counted in the household 399 size), although we also considered the sensitivity of our results to this assumption. 400 401 In two households, at least one household member developed symptoms 55-56 days prior to 402 the symptom onset date of the index case, with no other household members developing

symptoms (or returning a positive PCR or antibody test) between these dates. In contrast, the
maximum gap between successive symptom onset dates in the remaining households was 25
days. Data from these two households were excluded from our analyses, on the basis that the

406 virus was most likely introduced multiple times into these households.

407

408 <u>Models</u>

409 General modelling framework

410 We denote the force of infection exerted by a given infected host onto each susceptible

411 member of their household, at time  $\tau$  days since infection, by  $\beta(\tau)$ , where we assumed

412 
$$\beta(\tau) = (\beta_0/n)f(\tau),$$

413 if the host develops symptoms, and

414  $\beta(\tau) = \alpha_A(\beta_0/n)f(\tau),$ 

415 if the host remains asymptomatic. Here:

416 •  $\beta_0$  represents the overall infectiousness of a host who develops symptoms.

| 417 | • <i>n</i> is the household size. The scaling of $\beta(\tau)$ with $1/n$ corresponds to frequency-        |
|-----|--|
| 418 | dependent transmission, as assumed in [36, 52], although we considered alternative                         |
| 419 | possibilities where transmission was either density-dependent (without the scaling                         |
| 420 | factor $1/n$ ) or scaled with $1/n^{0.5}$ [51] in sensitivity analyses.                                    |
| 421 | • $f(\tau)$ is the generation time distribution.   |
| 422 | • $\alpha_A$ is the relative infectiousness of infected hosts who remain asymptomatic. We                  |
| 423 | assumed a value of 0.35 [32] in most of our analyses, although we also carried out                         |
| 424 | sensitivity analyses in which different values of $\alpha_A$ were considered.                              |
| 425 |  |
| 426 | Throughout, the normalised infectiousness profile, $f(\tau)$ , is referred to as the generation time       |
| 427 | distribution. However, realised generation times within a household may be shortened due to                |
| 428 | the depletion of susceptible household members before longer generation times can be                       |
| 429 | attained [6, 27]. For example, if an infected host was equally infectious at two times since               |
| 430 | infection, $\tau_1 < \tau_2$ , then we would have $f(\tau_1) = f(\tau_2)$ . However, because the number of |
| 431 | susceptible household members may decrease between these two times (i.e., either the host                  |
| 432 | under consideration, or another infected household member, may transmit the virus within the               |
| 433 | household in the intervening time), then household transmission is in fact more likely to                  |

434 occur in the household at the earlier time,  $\tau_1$ , when more susceptibles are available.

435 Therefore, we also predicted the mean and standard deviation of realised generation times

436 within the study households in the Supplementary Material (Figure S4).

-

437

438 We considered two different models of infectiousness, which are outlined below. Under each

439 model, expressions were derived in [12] for the generation time, time from onset of

440 symptoms to transmission (TOST) and serial interval distributions, in addition to the

441 proportion of transmissions occurring before symptom onset. These expressions are given in

the Supplementary Material (other than the generation time distribution and proportion of
presymptomatic transmissions for the independent transmission and symptoms model, which
are stated below).

445

446 Independent transmission and symptoms model

447 In this model, the infectiousness of an infected host (who does not remain asymptomatic

throughout infection; asymptomatic infected hosts are considered separately) at a given time

449 since infection,  $\tau$  days, is assumed to be independent of whether or not the host has yet

450 developed symptoms – i.e., the generation time and incubation period are independent. In this

451 case, the generation time distribution,  $f(\tau)$ , was assumed to be the probability density

452 function of a lognormal distribution [37] (an alternative case of a gamma distributed

453 generation time is considered in Figure S8). The mean and standard deviation of this

454 distribution, in addition to  $\beta_0$ , were estimated when we fitted the model to the household

455 transmission data.

456

Under the assumption of independent transmission and symptoms, the proportion of
transmissions occurring prior to symptom onset (among infectors who develop symptoms) is
given by [8, 53]

460 
$$\int_0^\infty f(\tau) (1 - F_{inc}(\tau)) d\tau$$

461 where  $F_{inc}$  is the cumulative distribution function of the incubation period (this was assumed 462 to be known; the exact incubation period distribution we used is given under "Parameter 463 estimation" below).

464

465 *Mechanistic model* 

| 466 | Under the mechanistic model [12], infectors who develop symptoms progress through                               |
|-----|---|
| 467 | independent latent ( $E$ ), presymptomatic infectious ( $P$ ) and symptomatic infectious ( $I$ ) stages.        |
| 468 | The duration of each stage was assumed to be gamma distributed, and infectiousness was                          |
| 469 | assumed to be constant during each stage. Under these assumptions, an explicit expression                       |
| 470 | can be derived for the expected infectiousness, $\beta(\tau \mid \tau_{inc})$ , of a host (who develops         |
| 471 | symptoms) at time since infection $\tau$ , conditional on their incubation period $\tau_{inc}$ . Details of the |
| 472 | mechanistic approach, including the formula for $\beta(\tau \mid \tau_{inc})$ , are provided in the             |
| 473 | Supplementary Material.   |
| 474 |   |
| 475 | When we fitted this model to the household transmission data, three model parameters were                       |
| 476 | estimated in addition to $\beta_0$ . These parameters correspond to:  |
| 477 | • The ratio between the mean latent $(E)$ period and the mean incubation (combined $E$                          |
| 478 | and $P$ ) period (where the latter was assumed known).  |
| 479 | • The mean symptomatic infectious ( <i>I</i> ) period.  |
| 480 | • The ratio between the transmission rates when potential infectors are in the $P$ and $I$                      |
| 481 | stages.   |
| 482 |   |
| 483 | Likelihood function   |
| 484 | The models were fitted to the household data using data augmentation Markov chain Monte                         |
| 485 | Carlo (MCMC; see further details below). For a household (of size $n$ ) in which $n_I$ household                |
| 486 | members are infected during the study (of whom $n_S$ develop symptoms and $n_A$ remain                          |
| 487 | asymptomatic throughout infection) and $n_U = n - n_I$ are uninfected, augmented data consist                   |
| 488 | of the entire sequence of infection times of individuals in the household $(t_1 < \cdots < t_{n_l})$ , as       |
| 489 | well as the exact symptom onset times $(t_{s,j})$ of each host, $j$ , who develops symptoms.                    |
| 490 |   |

When deriving an expression for the likelihood contribution from the household, given theseaugmented data, we made several simplifying assumptions:

- The virus was introduced once into each household (i.e., no subsequent infections
  from the community occurred following the infection of the primary case).
- No co-primary cases.
- Potential bias towards more recent infection of the primary host when community
- 497 prevalence was increasing, or less recent when prevalence was decreasing [8, 26, 38],
- 498 was neglected.
- 499

We denote the expected infectiousness of household member *j*, at time  $\tau$  since infection, by  $\beta_j(\tau)$ . For the mechanistic model in which transmission and symptoms are not independent, this infectiousness is conditional on the duration of the incubation period,  $t_{s,j} - t_j$ , if host *j* developed symptoms. The total (instantaneous) force of infection exerted at time *t* on each susceptible household member is then

506 
$$\lambda(t) = \sum_{j=1}^{n_I} \beta_j (t - t_j)$$

505 where  $\beta_j(t - t_j) = 0$  for  $t \le t_j$ , and the cumulative force of infection is

507 
$$\Lambda(t) = \int_{-\infty}^{t} \lambda(s) \mathrm{d}s.$$

508

For  $k = 2, ..., n_l$ , conditional on the sequence of infection times up to time  $t_k$ , the probability that host k becomes infected at time  $t_k$  is given by

511  $\lambda(t_k)\exp(-\Lambda(t_k)),$ 

512 where  $\exp(-\Lambda(t_k))$  represents the probability that host k avoided infection up to time t [36, 513 37].

515 For  $k = n_I + 1, ..., n$ , conditional on the entire sequence of infection times,  $t_1, ..., t_{n_I}$ , the

- probability that host k remains uninfected is given by  $\exp(-\Lambda(\infty))$ . In the case of
- 517 independent transmission and symptoms, we have

518 
$$\exp(-\Lambda(\infty)) = \exp(-\beta_0(n_s + \alpha_A n_A)/n))$$

519 whereas for the mechanistic model,  $\exp(-\Lambda(\infty))$  instead depends on the incubation periods

520 of those hosts who develop symptoms (see the Supplementary Material).

- 521
- 522 The likelihood contribution from the household,  $L(\theta)$ , where  $\theta$  is the vector of unknown
- 523 model parameters, given the augmented data, can therefore be written as

524 
$$L(\theta) = \prod_{k=1}^{n} L_{k,1}(\theta) L_{k,2}(\theta).$$

525 Here,  $L_{k,1}(\theta)$  is the contribution to the likelihood from the transmission, or absence of 526 transmission, to host k, i.e.,

527 
$$L_{k,1}(\theta) = \begin{cases} 1, & \text{for } k = 1; \\ \lambda(t_k) \exp(-\Lambda(t_k)), & \text{for } k = 2, ..., n_l; \\ \exp(-\Lambda(\infty)), & \text{for } k = n_l + 1, ..., n. \end{cases}$$

528  $L_{k,2}(\theta)$  is the contribution from the incubation period of host k (where applicable), i.e.,

529  $L_{k,2}(\theta) = \begin{cases} f_{inc}(t_{s,k} - t_k), & \text{if host } k \text{ becomes infected and develops symptoms;} \\ 1, & \text{otherwise;} \end{cases}$ 

530 where  $f_{inc}$  is the probability density function of the incubation period (this was assumed to be

531 known; the exact incubation period distribution we used is given below).

532

533 Each household was assumed to be independent, so that the overall likelihood was given by

- the product of the contributions from each household.
- 535

# 536 Parameter estimation

# 537 *Incubation period*

538 For the independent transmission and symptoms model, we assumed a lognormal incubation 539 period distribution with mean 5.8 days and standard deviation 3.1 days [31]. For the 540 mechanistic model, we assumed a gamma distributed incubation period with the same mean 541 and standard deviation; this was for mathematical convenience, since the incubation period 542 was decomposed into the sum of independent gamma distributed latent and presymptomatic 543 infectious periods. Results for the independent transmission and symptoms model using a 544 gamma distributed incubation period are shown in Figure S8, and we account for uncertainty 545 in the exact parameters of the incubation period distribution in Figure S9. 546 547 Parameter fitting procedure Unknown model parameters were estimated using data augmentation MCMC. The observed 548 549 data comprised information about whether or not individuals were ever infected and/or 550 displayed symptoms, symptom onset dates, and for some individuals an upper bound on the 551 infection time (corresponding to the date of a positive PCR test). These data were augmented 552 with precise times of infection and symptom onset (where applicable) for each host. No prior assumptions were made about the order of transmissions within the household. 553 554 Below, we outline the parameter fitting procedure that we used for the independent 555 556 transmission and symptoms model. The procedure used for the mechanistic model was 557 similar and is described in the Supplementary Material. 558

Lognormal priors were assumed for fitted model parameters (these parameters were the meanand standard deviation of the generation time distribution, in addition to the overall

561 infectiousness,  $\beta_0$ ). The priors for the mean and standard deviation of the generation time 562 distribution had medians of 5 days and 2 days, respectively (these choices were informed by 563 previous estimates of the SARS-CoV-2 generation time distribution [8, 13, 14]), and were 564 chosen to ensure a prior probability of only 0.025 that these parameters exceeded very high 565 values of 10 days and 7 days, respectively. The exact priors we used are detailed in Table S2.

566

567 We denote the vector of model parameters by  $\theta$ , and the augmented data by

568 
$$t = (t^{(1)}, ..., t^{(M)})$$

569 where  $t^{(m)}$  represents the augmented data from household m = 1, ..., M, and M is the total

570 number of households. We write the (overall) likelihood as

571 
$$L(\theta; \boldsymbol{t}) = \prod_{m=1}^{M} L^{(m)}(\theta; \boldsymbol{t}^{(m)}),$$

572 where the likelihood contribution,  $L^{(m)}(\theta; t^{(m)})$ , from each household, *m*, was computed as 573 described in the previous section, and denote the prior density of  $\theta$  by  $\pi(\theta)$ .

574

575 In each step of the chain, we carried out (in turn) one of the following:

576 1. Propose new values for the vector of model parameters,  $\theta$ , using independent 577 normal proposal distributions for each parameter (around the corresponding 578 parameter values in the previous step of the chain). Accept the proposed 579 parameters,  $\theta_{prop}$ , with probability

580 
$$\min\left(\frac{L(\theta_{prop}; \boldsymbol{t})\pi(\theta_{prop})}{L(\theta_{old}; \boldsymbol{t})\pi(\theta_{old})}, 1\right),$$

581 where  $\theta_{old}$  denotes the vector of parameter values from the previous step of 582 the chain, and where the augmented data, *t*, remain unchanged in this step. 583 2. Propose new values for the precise symptom onset times of each symptomatic 584 infected host, using independent uniform proposal distributions (within the

585 day of symptom of onset for each host). For each household, m, accept the 586 proposed augmented data,  $t_{prop}^{(m)}$ , from that household with probability

587 
$$\min\left(\frac{L^{(m)}\left(\theta; \boldsymbol{t}_{prop}^{(m)}\right)}{L^{(m)}\left(\theta; \boldsymbol{t}_{old}^{(m)}\right)}, 1\right),$$

588 where  $t_{old}^{(m)}$  denotes the corresponding augmented data from the previous step 589 of the chain, and where the model parameters,  $\theta$ , remain unchanged in this 590 step (i.e., proposed times are accepted/rejected independently for each 591 household, according to the likelihood contribution from that household).

592 3. Propose new values for the infection time of one randomly chosen 593 symptomatic infected host in each household (in households where there was 594 at least one), using independent normal proposal distributions (around the 595 equivalent times in the previous step of the chain). For each household, m, 596 accept the proposed augmented data,  $t_{prop}^{(m)}$ , from that household with 597 probability

$$\min\left(\frac{L^{(m)}\left(\theta; \boldsymbol{t}_{prop}^{(m)}\right)}{L^{(m)}\left(\theta; \boldsymbol{t}_{old}^{(m)}\right)}, 1\right).$$

5994. Propose new values for the infection time of one randomly chosen600asymptomatic infected host in each household (in households where there was601at least one), using independent normal proposal distributions (around the602equivalent times in the previous step of the chain). For each household, m,603accept the proposed augmented data,  $t_{prop}^{(m)}$ , from that household with604probability

605 
$$\min\left(\frac{L^{(m)}\left(\theta; \boldsymbol{t}_{prop}^{(m)}\right)}{L^{(m)}\left(\theta; \boldsymbol{t}_{old}^{(m)}\right)}, 1\right).$$

| 606        |   |
|------------|---|
| 607        | The chain was run for 10,000,000 iterations; the first 2,000,000 iterations were discarded as   |
| 608        | burn-in. Posteriors were obtained by recording only every 100 iterations of the chain.  |
| 609        |   |
| 610        |   |
| 611        | Governance statement:   |
| 612        | The household study was approved by the PHE Research Ethics and Governance Group as   |
| 613        | part of the portfolio of PHE's enhanced surveillance activities in response to the pandemic.  |
| 614        |   |
| 615        | Acknowledgments:  |
| 616        | Thanks to Pauline Waight, who managed the data for the household study, and to the PHE  |
| 617        | staff who collected the data and tested the PCR and serum samples. Thanks also to Rob   |
| 618        | Challen, Julia Gog, Matt Keeling and other members of the Juniper Consortium  |
| 619        | (www.maths.org/juniper/) for helpful comments about this research.  |
| 620        |   |
| 621        | Competing interests:  |
| 622        | AE received a research grant from Taisho Pharmaceutical Co., Ltd. All the other authors   |
| 623        | declare no competing interests.   |
| 624        |   |
| 625        | References:   |
| 626<br>627 | <ul> <li>[1] Anderson RM, May RM. Infectious Diseases of Humans: Dynamics and Control. OUP<br/>Oxford, 1992.</li> </ul>                                     |
| 628<br>629 | [2] Diekmann O, Heesterbeek JAP. Mathematical Epidemiology of Infectious Diseases:<br>Model Building, Analysis and Interpretation. John Wiley & Sons, 2000. |

- [3] Wallinga J, Lipsitch M. How generation intervals shape the relationship between growth
   rates and reproductive numbers. *Proc R Soc B Biol Sci* 2007; 274: 599–604.
- 632 [4] Svensson Å. A note on generation times in epidemic models. *Math Biosci* 2007; 208:
  633 300–311.
- 634 [5] Griffin J, Casey M, Collins Á, et al. Rapid review of available evidence on the serial 635 interval and generation time of COVID-19. *BMJ Open* 2020; 10: e040263.
- 636 [6] Fraser C. Estimating Individual and Household Reproduction Numbers in an Emerging 637 Epidemic. *PLOS ONE* 2007; 2: e758.
- 638 [7] Ashcroft P, Lehtinen S, Angst DC, et al. Quantifying the impact of quarantine duration on 639 COVID-19 transmission. *eLife* 2021; 10: e63704.
- 640 [8] Ferretti L, Wymant C, Kendall M, et al. Quantifying SARS-CoV-2 transmission suggests 641 epidemic control with digital contact tracing. *Science* 2020; 368: eabb6936.
- 642 [9] Gostic KM, McGough L, Baskerville EB, et al. Practical considerations for measuring the 643 effective reproductive number, Rt. *PLOS Comput Biol* 2020; 16: e1008409.
- [10] Abbott S, Hellewell J, Thompson RN, et al. Estimating the time-varying reproduction
   number of SARS-CoV-2 using national and subnational case counts. *Wellcome Open Res* 2020; 5: 112.
- [11] Thompson RN, Hollingsworth TD, Isham V, et al. Key questions for modelling COVID19 exit strategies. *Proc R Soc B Biol Sci* 2020; 287: 20201405.
- [12] Hart WS, Maini PK, Thompson RN. High infectiousness immediately before COVID-19
   symptom onset highlights the importance of continued contact tracing. *eLife* 2021; 10:
   e65534.
- [13] Ferretti L, Ledda A, Wymant C, et al. The timing of COVID-19 transmission. *medRxiv*2020; 2020.09.04.20188516.
- [14] Ganyani T, Kremer C, Chen D, et al. Estimating the generation interval for coronavirus
   disease (COVID-19) based on symptom onset data, March 2020. *Eurosurveillance* 2020; 25: 2000257.
- [15] Sun K, Wang W, Gao L, et al. Transmission heterogeneities, kinetics, and controllability
   of SARS-CoV-2. *Science* 2021; 371: eabe2424.
- [16] Hu S, Wang W, Wang Y, et al. Infectivity, susceptibility, and risk factors associated with
   SARS-CoV-2 transmission under intensive contact tracing in Hunan, China. *Nat Commun* 2021; 12: 1533.
- [17] Cheng H-Y, Jian S-W, Liu D-P, et al. Contact tracing assessment of COVID-19
   transmission dynamics in Taiwan and risk at different exposure periods before and
   after symptom onset. *JAMA Intern Med* 2020; 180: 1156.
- [18] Xia W, Liao J, Li C, et al. Transmission of corona virus disease 2019 during the
  incubation period may lead to a quarantine loophole. *medRxiv* 2020;
  2020.03.06.20031955.

- [19] Zhang J, Litvinova M, Wang W, et al. Evolving epidemiology and transmission
  dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive
  and modelling study. *Lancet Infect Dis* 2020; 20: 793–802.
- 671 [20] He X, Lau EHY, Wu P, et al. Temporal dynamics in viral shedding and transmissibility 672 of COVID-19. *Nat Med* 2020; 26: 672–675.
- 673 [21] Ali ST, Wang L, Lau EHY, et al. Serial interval of SARS-CoV-2 was shortened over time 674 by nonpharmaceutical interventions. *Science* 2020; 369: 1106–1109.
- [22] Bushman M, Worby C, Chang H-H, et al. Transmission of SARS-CoV-2 before and
   after symptom onset: impact of nonpharmaceutical interventions in China. *Eur J Epidemiol* 2021; 36: 429–439.
- [23] Challen R, Brooks-Pollock E, Tsaneva-Atanasova K, et al. Meta-analysis of the SARS CoV-2 serial interval and the impact of parameter uncertainty on the COVID-19
   reproduction number. *medRxiv* 2020; 2020.11.17.20231548.
- [24] Public Health England. "The First Few Hundred (FF100)" Enhanced Case and Contact
   Protocol v12. 2020.
- [25] Boddington NL, Charlett A, Elgohari S, et al. COVID-19 in Great Britain:
  epidemiological and clinical characteristics of the first few hundred (FF100) cases: a
  descriptive case series and case control analysis. *medRxiv* 2020;
  2020.05.18.20086157.
- [26] Lehtinen S, Ashcroft P, Bonhoeffer S. On the relationship between serial interval,
   infectiousness profile and generation time. *J R Soc Interface* 2021; 18: 20200756.
- [27] Cauchemez S, Donnelly CA, Reed C, et al. Household Transmission of 2009 Pandemic
   Influenza A (H1N1) Virus in the United States. *N Engl J Med* 2009; 361: 2619–2627.
- [28] Ashcroft P, Huisman JS, Lehtinen S, et al. COVID-19 infectivity profile correction. Swiss
   Med Wkly 2020; 150: w20336.
- Wells CR, Townsend JP, Pandey A, et al. Optimal COVID-19 quarantine and testing
   strategies. *Nat Commun* 2021; 12: 356.
- [30] Manfredi P, D'Onofrio A (eds). Modeling the Interplay Between Human Behavior and
   the Spread of Infectious Diseases. New York: Springer-Verlag, 2013.
- [31] McAloon C, Collins Á, Hunt K, et al. Incubation period of COVID-19: a rapid systematic
   review and meta-analysis of observational research. *BMJ Open* 2020; 10: e039652.
- [32] Buitrago-Garcia D, Egli-Gany D, Counotte MJ, et al. Occurrence and transmission
   potential of asymptomatic and presymptomatic SARS-CoV-2 infections: A living
   systematic review and meta-analysis. *PLOS Med* 2020; 17: e1003346.
- [33] Deng Y, You C, Liu Y, et al. Estimation of incubation period and generation time based
   on observed length-biased epidemic cohort with censoring for COVID-19 outbreak in
   China. *Biometrics*; 1–13.
- [34] Knight J, Mishra S. Estimating effective reproduction number using generation time
   versus serial interval, with application to covid-19 in the Greater Toronto Area,
   Canada. *Infect Dis Model* 2020; 5: 889–896.

- [35] Bacallado S, Zhao Q, Ju N. Letter to the editor: Generation interval for COVID-19
   based on symptom onset data. *Eurosurveillance* 2020; 25: 2001381.
- [36] Cauchemez S, Carrat F, Viboud C, et al. A Bayesian MCMC approach to study
   transmission of influenza: application to household longitudinal data. *Stat Med* 2004;
   23: 3469–3487.
- Ferguson NM, Cummings DAT, Cauchemez S, et al. Strategies for containing an
   emerging influenza pandemic in Southeast Asia. *Nature* 2005; 437: 209–214.
- [38] Britton T, Scalia Tomba G. Estimation in emerging epidemics: biases and remedies. J
   *R Soc Interface* 2019; 16: 20180670.
- [39] Knock ES, Whittles LK, Lees JA, et al. The 2020 SARS-CoV-2 epidemic in England:
  key epidemiological drivers and impact of interventions. *medRxiv* 2021;
  2021.01.11.21249564.
- [40] Pouwels KB, House T, Pritchard E, et al. Community prevalence of SARS-CoV-2 in
   England from April to November, 2020: results from the ONS Coronavirus Infection
   Survey. *Lancet Public Health* 2021; 6: e30–e38.
- [41] Park SW, Bolker BM, Funk S, et al. Roles of generation-interval distributions in shaping
   relative epidemic strength, speed, and control of new SARS-CoV-2 variants. *medRxiv* 2021; 2021.05.03.21256545.
- [42] Public Health England. SARS-CoV-2 variants of concern and variants under
   investigation in England. Technical briefing 7, 2021.
- [43] Davies NG, Abbott S, Barnard RC, et al. Estimated transmissibility and impact of
   SARS-CoV-2 lineage B.1.1.7 in England. *Science* 2021; eabg3055.
- [44] Volz E, Mishra S, Chand M, et al. Transmission of SARS-CoV-2 Lineage B.1.1.7 in
   England: Insights from linking epidemiological and genetic data. *medRxiv* 2021;
   2020.12.30.20249034.
- [45] Kissler SM, Fauver JR, Mack C, et al. Densely sampled viral trajectories suggest longer
   duration of acute infection with B.1.1.7 variant relative to non-B.1.1.7 SARS-CoV-2.
   *medRxiv* 2021; 2021.02.16.21251535.
- [46] Cevik M, Kuppalli K, Kindrachuk J, et al. Virology, transmission, and pathogenesis of
   SARS-CoV-2. *BMJ* 2020; 371: m3862.
- [47] Hart WS, Maini PK, Yates CA, et al. A theoretical framework for transitioning from
  patient-level to population-scale epidemiological dynamics: influenza A as a case
  study. *J R Soc Interface* 2020; 17: 20200230.
- [48] Ke R, Zitzmann C, Ribeiro RM, et al. Kinetics of SARS-CoV-2 infection in the human
   upper and lower respiratory tracts and their relationship with infectiousness. *medRxiv* 2020; 2020.09.25.20201772.
- 744[49] Marc A, Kerioui M, Blanquart F, et al. Quantifying the relationship between SARS-CoV-7452 viral load and infectiousness. *medRxiv* 2021; 2021.05.07.21256341.
- [50] Jones TC, Biele G, Mühlemann B, et al. Estimating infectiousness throughout SARS CoV-2 infection course. *Science* 2021; eabi5273.

- [51] Endo A, Uchida M, Kucharski AJ, et al. Fine-scale family structure shapes influenza transmission risk in households: Insights from primary schools in Matsumoto city, 2014/15. *PLOS Comput Biol* 2019; 15: e1007589.
- [52] Cauchemez S, Ferguson NM, Fox A, et al. Determinants of influenza transmission in
   South East Asia: insights from a household cohort study in Vietnam. *PLOS Pathog* 2014; 10: e1004310.
- [53] Fraser C, Riley S, Anderson RM, et al. Factors that make an infectious disease
   outbreak controllable. *Proc Natl Acad Sci* 2004; 101: 6146–6151.